Drug intelligence / Profile preview

HL-016

Development stage: Preclinical
Lead developer: Shanghai KeChow Pharmaceuticals
Modality: Small Molecules

Overview

HL-016 is an investigational small molecule targeted therapy being developed by Kechow Pharma for the treatment of brain tumors. It is currently in the preclinical research stage. While the specific molecular target has not been disclosed, the drug is part of Kechow Pharma's oncology pipeline, which focuses on developing precision medicines for solid tumors. As a targeted therapy, it is designed to address specific molecular pathways involved in the progression of central nervous system malignancies.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on HL-016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL-016.

Explore the full profile